Previous 10 | Next 10 |
Invitae ( NYSE: NVTA ) will undertake an operational realignment that the medical genetics company said will lead to $326 million in annual cost savings by 2023. Shares are down 1.5% in after-hours trading. The move will also extend's Invitae's ( NVTA ) cash ru...
Invitae ( NYSE: NVTA ) shares surged over 10% during extended trading after the medical genetics company announced leadership changes, with COO Kenneth Knight taking over as CEO and as a member of the board of directors, effective immediately. Knight succeeds Sean Geor...
Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow and Realize Full Potential of Industry-Leading Genetics Testing Platform PR Newswire — Exiting non-core businesses and geographies to prioritize higher-margin business ...
Invitae Announces Leadership Transition PR Newswire — COO Kenneth D. Knight named CEO succeeding Sean George ; Dr. George to continue as member of Board of Directors — — Co-Founder and former CEO Randy Scott returns as chairman ...
ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...
Invitae ( NYSE: NVTA ) has partnered with contract research organization Worldwide Clinical Trials to provide use for the first time of its Explorer system , which provides access to aggregated genetic testing results. Data insights provided are based on based on preva...
Bear markets are a time of significant volatility; the tide goes out, and virtually all stocks can fall, regardless of whether they're strong companies. The trick is identifying the damaged stocks with solid business fundamentals behind them because they're most likely to rebound, soaring t...
Tech stocks have crashed, but Wall Street should eventually remember why the love affair began in the first place. After the tech crash, it makes sense to invest in a large quantity of names. Even so, this isn't an excuse to buy anything and everything. Don’t waste your tim...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
There’s only one week left until we turn the page on June and the second quarter. With GDP numbers and more CPI data expected to show the progress in curbing inflation, the market’s risk appetite seems to change daily. But one of the more static trends in the stock market toda...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...